Skip to content

Kaleido Biosciences, Inc.

Delisted

CIK 1751299fmd_1R50K4T1MAG20T5MSP0C1S42ZEManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard

Coverage: Jan 01, 2018 to Dec 31, 2021, 16 periods

Latest annual · FY2021

Millions
Total revenues
1
Operating income
(88)
Net income
(90)
Free cash flow
(78)

Latest quarter · Q4 FY2021

Millions
Total revenues
0
Operating income
(20)
Net income
(20)
Free cash flow
(18)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2018 to FY2021
n/m

Kaleido Biosciences, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2021FY2020ChangeSource
Revenue$1.1 million$975,000+13.2%10-K 2022-04-01 · proof
Operating income-$87.7 million-$78.9 million10-K 2022-04-01 · proof
Net income-$90.3 million-$81.6 million10-K 2022-04-01 · proof
Cash from operating activities-$77.1 million-$61.5 million10-K 2022-04-01 · proof
Free cash flow-$78.2 million-$65.5 million10-K 2022-04-01 · proof
Total assets$50.1 million$59.3 million-15.5%10-K 2022-04-01 · proof
Total liabilities$39.5 million$38.8 million+1.8%10-K 2022-04-01 · proof
Cash and cash equivalents$38.5 million$46.2 million-16.8%10-K 2022-04-01 · proof
Total debt$21.7 million$21 million+3.3%10-K 2022-04-01 · proof
What was Kaleido Biosciences, Inc.'s revenue in fiscal 2021?
Kaleido Biosciences, Inc. reported revenue of $1.1 million for fiscal 2021 (the year ended Dec 31, 2021), against $975,000 the year before (+13.2%). Source: the 10-K filed with the SEC on Apr 1, 2022. SEC
What was Kaleido Biosciences, Inc.'s operating income in fiscal 2021?
Kaleido Biosciences, Inc. reported operating income of -$87.7 million for fiscal 2021 (the year ended Dec 31, 2021), against -$78.9 million the year before. Source: the 10-K filed with the SEC on Apr 1, 2022. SEC
What was Kaleido Biosciences, Inc.'s net income in fiscal 2021?
Kaleido Biosciences, Inc. reported net income of -$90.3 million for fiscal 2021 (the year ended Dec 31, 2021), against -$81.6 million the year before. Source: the 10-K filed with the SEC on Apr 1, 2022. SEC
What was Kaleido Biosciences, Inc.'s cash from operating activities in fiscal 2021?
Kaleido Biosciences, Inc. reported cash from operating activities of -$77.1 million for fiscal 2021 (the year ended Dec 31, 2021), against -$61.5 million the year before. Source: the 10-K filed with the SEC on Apr 1, 2022. SEC
What was Kaleido Biosciences, Inc.'s free cash flow in fiscal 2021?
Kaleido Biosciences, Inc. reported free cash flow of -$78.2 million for fiscal 2021 (the year ended Dec 31, 2021), against -$65.5 million the year before. Source: the 10-K filed with the SEC on Apr 1, 2022. SEC
What are Kaleido Biosciences, Inc.'s total assets?
As of Dec 31, 2021, Kaleido Biosciences, Inc. reported total assets of $50.1 million, against $59.3 million a year earlier (-15.5%). Source: the 10-K filed with the SEC on Apr 1, 2022. SEC
What are Kaleido Biosciences, Inc.'s total liabilities?
As of Dec 31, 2021, Kaleido Biosciences, Inc. reported total liabilities of $39.5 million, against $38.8 million a year earlier (+1.8%). Source: the 10-K filed with the SEC on Apr 1, 2022. SEC
What are Kaleido Biosciences, Inc.'s cash and cash equivalents?
As of Dec 31, 2021, Kaleido Biosciences, Inc. reported cash and cash equivalents of $38.5 million, against $46.2 million a year earlier (-16.8%). Source: the 10-K filed with the SEC on Apr 1, 2022. SEC
What is Kaleido Biosciences, Inc.'s total debt?
As of Dec 31, 2021, Kaleido Biosciences, Inc. reported total debt of $21.7 million, against $21 million a year earlier (+3.3%). Source: the 10-K filed with the SEC on Apr 1, 2022. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1751299&period_type=annual&limit=5"

Information only, not investment advice.